Penn Gene Therapy Program Director James Wilson will leave the University following the transfer of Penn Medicine’s Gene Therapy Program to two new for-profit companies: GEMMA Biotherapeutics and Franklin Biolabs.
Penn Gene Therapy Program Director James Wilson will leave the University following the transfer of Penn Medicine’s Gene Therapy Program to two new for-profit companies: GEMMA Biotherapeutics and Franklin Biolabs.